D. Katzenstein

发表

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 1996, The New England journal of medicine.

Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

T. Silander, D. Katzenstein, Y. Moreau, 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Bayesian network analyses of resistance pathways against efavirenz and nevirapine

D. Katzenstein, R. Shafer, M. Soares, 2008, AIDS.

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy

D. Katzenstein, R. Shafer, R. Kantor, 2004, AIDS.

Non-Nucleoside Phenotypic Hypersusceptibility Cut-Point Determination from ACTG 359

D. Katzenstein, R. Haubrich, R. Swanstrom, 2007, HIV clinical trials.

Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers.

D. Katzenstein, W. Mcfarland, J. Parsonnet, 1999, The Journal of infectious diseases.

Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel

Michael S Saag, Mauro Schechter, Paul A Volberding, 2006 .

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Michael S Saag, Mauro Schechter, Paul A Volberding, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel

M A Fischl, B G Gazzard, S. Hammer, 2000 .

Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB1 in adults coinfected with Mycobacterium tuberculosis in Harare, Zimbabwe.

D. Katzenstein, L. Zijenah, L. Louie, 2002, Human immunology.

Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.

D. Katzenstein, R. Kantor, Davey M. Smith, 2012, Journal of acquired immune deficiency syndromes.

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.

D. Katzenstein, M. Hughes, R. Shafer, 2001, Journal of acquired immune deficiency syndromes.

HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.

D. Katzenstein, M. Hughes, T. Merigan, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.

D. Katzenstein, T. Merigan, R. Shafer, 1993, Journal of virological methods.

Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction

D. Katzenstein, T. Merigan, M. Winters, 1993, Journal of clinical microbiology.

Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.

D. Katzenstein, J. Bartlett, N. Kumarasamy, 2016, The Journal of infectious diseases.

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe

D. Katzenstein, M. Egger, A. Spoerri, 2018 .

HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program

D. Katzenstein, J. Klausner, D. Israelski, 2015, PloS one.

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1

Tommy F. Liu, D. Katzenstein, R. Shafer, 2013, Antimicrobial Agents and Chemotherapy.

Detection of HIV-1 in Saliva: Implications for Case-Identification, Clinical Monitoring and Surveillance for Drug Resistance§

D. Katzenstein, M. Winters, J. Klausner, 2010, The open virology journal.

Combition therapies for HIV infection and genomic durg resistance

D. Katzenstein, 1997, The Lancet.

Virologic and CD 4 1 Cell Responses to New Nucleoside Regimens : Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection

S. Hammer, D. Katzenstein, M. Hughes, 2004 .

Infant feeding practices of HIV-infected and uninfected women in Zimbabwe.

D. Katzenstein, Y. Maldonado, M. Bassett, 2004, AIDS patient care and STDs.

Nosocomial adenovirus infections: molecular epidemiology of an outbreak due to adenovirus 3a.

D. Katzenstein, J. Cherrington, F. Rhame, 1988, The Journal of infectious diseases.

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

D. Katzenstein, T. Merigan, B. Smoller, 1999 .

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

D. Katzenstein, T. Merigan, P. Haslett, 1996, The Journal of infectious diseases.

Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months

D. Katzenstein, L. Mofenson, H. Coovadia, 2003, Journal of acquired immune deficiency syndromes.

HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe

D. Katzenstein, G. Woelk, C. Gore-felton, 2012, AIDS care.

Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe

D. Katzenstein, S. Kassaye, G. Woelk, 2009, AIDS care.

Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis

D. Katzenstein, D. Owens, E. Bendavid, 2009, Journal of acquired immune deficiency syndromes.

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.

D. Katzenstein, G. Sanders, D. Owens, 2008, Archives of internal medicine.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

D. Katzenstein, K. Tashima, P. Sax, 2011, The Journal of infectious diseases.

Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5)

D. Katzenstein, S. Kassaye, L. Zijenah, 2010, AIDS.

Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study

D. Katzenstein, Z. El-Khatib, M. Petzold, 2011, BMC public health.

Rapid Communication: Efavirenz‐ and Adefovir Dipivoxil‐Based Salvage Therapy in Highly Treatment‐Experienced Patients: Clinical and Genotypic Predictors of Virologic Response

D. Katzenstein, R. Shafer, A. Zolopa, 2000, Journal of acquired immune deficiency syndromes.

Learning and doing: operational research and access to HIV treatment in Africa

D. Katzenstein, J. Moatti, M. Laga, 2010, AIDS.

Placental malaria and mother-to-child transmission of human immunodeficiency virus-1 in rural Rwanda.

D. Katzenstein, M. Zink, A. Saah, 2011, The American journal of tropical medicine and hygiene.

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Thorsteinn S. Rögnvaldsson, Philip L. Tzou, D. Katzenstein, 2017, Scientific Reports.

HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya

D. Katzenstein, J. Hogan, L. Diero, 2014, Journal of the International AIDS Society.

Inhibition of human immunodeficiency virus gene amplification by heparin

D. Katzenstein, T. Merigan, M. Holodniy, 1991, Journal of clinical microbiology.

Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.

D. Katzenstein, D. Katzenstein, J. Min, 1999, AIDS research and human retroviruses.

Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe.

D. Katzenstein, Rena C. Patel, G. Kadzirange, 2010, African journal of reproductive health.

Cytomegalovirus and Epstein–Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis

D. Katzenstein, G. Woelk, L. Zijenah, 2008, AIDS (London).

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

D. Katzenstein, R. Haubrich, S. Lagakos, 2002, The Journal of infectious diseases.

Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884

D. Katzenstein, R. Haubrich, M. Fischl, 2000, AIDS.

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

D. Katzenstein, R. Haubrich, R. Swanstrom, 2008, AIDS research and human retroviruses.

Antiretroviral treatment in resource-poor settings: clinical research priorities

D. Katzenstein, H. Masur, J. Mukherjee, 2002, The Lancet.

AIDS Care : Psychological and Socio-medical Aspects of AIDS / HIV

D. Katzenstein, D. Israelski, L. Thairu, 2011 .

HIV treatment in developing countries

D. Katzenstein, P. Mason, 2000, Current infectious disease reports.

Maternal HIV‐1 Antibody and Vertical Transmission in Subtype C Virus Infection

D. Katzenstein, M. Mbizvo, H. Guevara, 2002, Journal of acquired immune deficiency syndromes.

The evaluation of the HIV/AIDS Drug Access Initiatives in Côte D'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa

D. Katzenstein, J. Moatti, M. Laga, 2003, AIDS.

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

D. Katzenstein, T. Merigan, B. Smoller, 1999, Journal of acquired immune deficiency syndromes.

Risk factors for HIV infection at enrollment in an urban male factory cohort in Harare, Zimbabwe.

D. Katzenstein, J. H. van de Wijgert, W. Mcfarland, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

The point of point-of-care testing

D. Katzenstein, S. Kassaye, 2011, The Lancet.

Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy

D. Katzenstein, C. Yiannoutsos, D. Clifford, 2001, Neurology.

Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe

D. Katzenstein, T. Wilsgaard, R. Ferrand, 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe.

D. Katzenstein, M. Mbizvo, M. Munjoma, 1999, The Journal of infectious diseases.

Cytomegalovirus viremia detected by molecular hybridization and electron microscopy.

D. Katzenstein, D. Martin, M. Jordan, 1984, Annals of internal medicine.

The Incidence and Correlates of Symptomatic and Asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Selected Populations in Five Countries

Annette M. Green, D. Katzenstein, R. Detels, 2011, Sexually transmitted diseases.

Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity.

R. M. Hendry, D. Katzenstein, M. Winters, 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

D. Katzenstein, R. Kantor, K. Mayer, 2009, Journal of virological methods.

Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells.

D. Katzenstein, T. Merigan, R. Wood, 1993, Journal of acquired immune deficiency syndromes.

Genital ulcers and transmission of HIV among couples in Zimbabwe.

D. Katzenstein, M. Bassett, S. Houston, 1989, AIDS (London).

Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa

D. Katzenstein, Z. El-Khatib, M. Petzold, 2011, PloS one.

Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm3(ACTG 175)

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of Infectious Diseases.

Antimicrobial susceptibility patterns amongst group B streptococci from women in Harare, Zimbabwe.

D. Katzenstein, P. Mason, S. Ray, 1996, International journal of antimicrobial agents.

susceptibility patterns amongst group B streptococci women in Harare, Zimbabwe from

D. Katzenstein, J. Wijgert, P. Mason, 1996 .

Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures.

D. Katzenstein, T. Merigan, M. Winters, 1992, PCR methods and applications.

Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis

D. Katzenstein, M. Winters, R. Bosch, 2011, HIV clinical trials.

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

D. Katzenstein, T. Merigan, S. Kundu, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Issues in the evaluation of AIDS vaccines.

D. Katzenstein, L. Sawyer, G. Quinnan, 1988, AIDS (London).

Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review

D. Katzenstein, R. Shafer, S. Rhee, 2021, The Lancet. Microbe.

Infection from Southern Africa Individuals with Early Subtype C HIV Type 1 Conserved Regions of Gag Targeted by Novel and Promiscuous CTL Epitopes in

D. Katzenstein, C. Gray, H. Sheppard, 2004 .

Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood.

D. Katzenstein, P. Mason, C. Contag, 2000 .

HIV viral load quantification, HIV resistance, and antiretroviral therapy.

D. Katzenstein, M. Holodniy, 1995, AIDS clinical review.

Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes

D. Katzenstein, J. Hogan, S. Istrail, 2015, Open forum infectious diseases.

Report of sexually transmitted diseases by HIV infected men during follow up: time to target the HIV infected?

D. Katzenstein, M. Mbizvo, M. Bassett, 2000, Sexually transmitted infections.

Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe.

D. Katzenstein, W. Mcfarland, R. Burke, 1998, The Journal of infectious diseases.

Antimicrobial resistance in gonococci isolated from patients and from commercial sex workers in Harare, Zimbabwe.

D. Katzenstein, D. Katzenstein, P. Mason, 1997, International journal of antimicrobial agents.

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection

D. Katzenstein, M. Jacobson, R. Pollard, 2002, AIDS.

Signal-Boosted Qualitative Ultrasensitive p24 Antigen Assay for Diagnosis of Subtype C HIV-1 Infection in Infants Under the Age of 2 Years

D. Katzenstein, S. Rusakaniko, L. Zijenah, 2005, Journal of acquired immune deficiency syndromes.

T lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years

D. Katzenstein, G. Janossy, S. Rusakaniko, 2005, Journal of Translational Medicine.

Human immunodeficiency virus in plasma and genital secretions during the menstrual cycle.

D. Katzenstein, J. Mullins, C. Goulston, 1996, The Journal of infectious diseases.

Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction.

D. Katzenstein, T. Merigan, M. Holodniy, 1991, The Journal of infectious diseases.

Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.

D. Katzenstein, T. Merigan, M. Winters, 1996, The Journal of infectious diseases.

Microbial flora of the lower genital tract of women in labour at Harare Maternity Hospital. The Puerperal Sepsis Study Group.

D. Katzenstein, P. Mason, T. Chimbira, 1989, The Central African journal of medicine.

Vaginal flora of women admitted to hospital with signs of sepsis following normal delivery, cesarean section or abortion. The Puerperal Sepsis Study Group.

D. Katzenstein, P. Mason, T. Chimbira, 1989, The Central African journal of medicine.

Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy.

D. Katzenstein, T. Merigan, M. Winters, 1993, The Journal of infectious diseases.

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa.

Xiaohua Xia, Lynn Morris, Clive M Gray, 2005, AIDS research and human retroviruses.

Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial.

D. Katzenstein, V. DeGruttola, M. Ragni, 1995, The Journal of infectious diseases.

Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.

D. Katzenstein, R. Ogden, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time

D. Katzenstein, D. Stevens, K. Clemons, 2015, Critical reviews in microbiology.

Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe.

D. Katzenstein, W. Mcfarland, J. Kahn, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Risk factors for HIV seropositivity among first‐time blood donors in Zimbabwe

D. Katzenstein, W. Mcfarland, D. Katzenstein, 1998, Transfusion.

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Michael S Saag, Mauro Schechter, Paul A Volberding, 2002, JAMA.

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

S. Hammer, D. Katzenstein, R. Schooley, 1998, JAMA.

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

S. Hammer, D. Katzenstein, R. Schooley, 1997, JAMA.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 1996, The New England journal of medicine.

Correlation of morphologic diagnosis of Pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction.

D. Katzenstein, W. Blumenfeld, M. Holodniy, 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

Douglas D. Richman, Julio S. G. Montaner, Martin S. Hirsch, 1996 .

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

S. Hammer, D. Katzenstein, R. Schooley, 1996, JAMA.

Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment

D. Katzenstein, M. Gandhi, J. Metcalfe, 2017, Journal of acquired immune deficiency syndromes.

Detection and Qualification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction

D. Katzenstein, T. Merigan, M. Holodniy, 1991 .

Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction.

D. Katzenstein, T. Merigan, M. Holodniy, 1991, The Journal of infectious diseases.

Practical guidelines in antiviral therapy

D. Katzenstein, D. Cooper, C. Boucher, 2002 .

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

D. Katzenstein, K. Marder, K. Tashima, 2007, Neurology.

Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance

D. Katzenstein, E. Keeffe, D. Israelski, 2008, International journal of STD & AIDS.

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

D. Katzenstein, R. Haubrich, S. Lagakos, 2000, The Journal of infectious diseases.

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

D. Katzenstein, T. Merigan, R. Shafer, 1994, The Journal of infectious diseases.

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

D. Katzenstein, R. Haubrich, E. Acosta, 2004, The Journal of infectious diseases.

Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

D. Katzenstein, P. Bulterys, S. Dalai, 2010, Clinics in perinatology.

Immunopathogenesis of AIDS

D. Katzenstein, L. Zijenah, 2002 .

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

D. Katzenstein, T. Merigan, R. Shafer, 1998, The Journal of clinical investigation.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis

D. Katzenstein, R. Shafer, D. Pillay, 2019, EClinicalMedicine.

Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.

D. Katzenstein, R. Kantor, 2003, AIDS reviews.

Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe

D. Katzenstein, T. Merigan, R. Shafer, 1997, Journal of virology.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens

D. Katzenstein, R. Bosch, B. Pinsky, 2019, Open forum infectious diseases.

Sustainable HIV treatment in Africa through viral-load-informed differentiated care

Jeffrey W. Eaton, Rosanna Peeling, Zachary Katz, 2015, Nature.

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2005, PLoS medicine.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

D. Katzenstein, M. Hughes, R. Shafer, 2002, Journal of acquired immune deficiency syndromes.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

S. Hammer, D. Katzenstein, S. Liou, 2001, The New England journal of medicine.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1–Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077

D. Katzenstein, R. D’Aquila, R. Bosch, 2014, PloS one.

Neuromuscular function in HIV infection: analysis of a placebo‐controlled combination antiretroviral trial

S. Hammer, D. Katzenstein, M. Hughes, 1998, AIDS.

HIV/AIDS care and treatment in sub-Saharan Africa.

D. Katzenstein, S. Kassaye, 2003, AIDS reviews.

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

D. Katzenstein, P. Sax, E. Daar, 2011, Annals of Internal Medicine.

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

S. Hammer, D. Katzenstein, R. Schooley, 2004, JAMA.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

S. Hammer, D. Katzenstein, C. Spino, 2000, Journal of acquired immune deficiency syndromes.

Genetic Analyses of HIV-1 env Sequences Demonstrate Limited Compartmentalization in Breast Milk and Suggest Viral Replication within the Breast That Increases with Mastitis

D. Katzenstein, J. Mullins, L. Heath, 2010, Journal of Virology.

Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.

D. Katzenstein, M. Winters, R. Kantor, 2007, AIDS research and human retroviruses.

Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milk.

D. Katzenstein, G. Woelk, L. Zijenah, 2007, The Journal of infectious diseases.

Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.

D. Katzenstein, C. Contag, L. Mofenson, 2005, The Journal of infectious diseases.

Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS Research and Human Retroviruses.

Drug Resistance and Heterogeneous Long-Term Virologic Responses of Human Immunodeficiency Virus Type 1-Infected Subjects to Zidovudine and Didanosine Combination Therapy

Robert W. Shafer, David Katzenstein, D. Katzenstein, 1995 .

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

D. Katzenstein, R. Haubrich, R. Swanstrom, 2004, The Journal of infectious diseases.

Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories

D. Katzenstein, J. Bremer, P. Reichelderfer, 1996, Journal of clinical microbiology.

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.

S. Hammer, D. Katzenstein, M. Hughes, 2001, AIDS research and human retroviruses.

Characterizing patterns of drug‐taking behavior with a multiple drug regimen in an AIDS clinical trial

D. Katzenstein, L. Sheiner, P. Girard, 1998, AIDS.

Virologic and CD 4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection

D. Katzenstein, M. Hughes, S. Liou, 2004 .

A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection

D. Katzenstein, C. Yiannoutsos, D. Clifford, 2000, Neurology.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy

D. Katzenstein, C. Yiannoutsos, D. Clifford, 2002, Neurology.

Role of blocking antibody in disseminated gonococcal infection.

D. Katzenstein, J. McCutchan, A. Braude, 1978, Journal of immunology.

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

D. Katzenstein, R. Shafer, P. Hsu, 1999, AIDS research and human retroviruses.

Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control.

D. Katzenstein, T. Merigan, 1991, Reviews of infectious diseases.

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.

D. Katzenstein, T. Merigan, M. Holodniy, 1992, Journal of acquired immune deficiency syndromes.

The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe

D. Katzenstein, Y. Maldonado, P. Mateta, 2005, International journal of STD & AIDS.

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.

B. Efron, D. Katzenstein, T. Merigan, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect

D. Katzenstein, T. Merigan, J. Montoya, 1993, Journal of clinical microbiology.

Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.

D. Katzenstein, T. Merigan, D. Israelski, 1991, The Journal of clinical investigation.

Sexual behavior and risk factors for HIV infection in a group of male factory workers who donated blood in Harare, Zimbabwe.

D. Katzenstein, M. Bassett, A. Latif, 1992, Journal of acquired immune deficiency syndromes.

Condom use and the risk of HIV infection: who is being protected?

D. Katzenstein, W. Mcfarland, M. Mbizvo, 1994, The Central African journal of medicine.

Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe

D. Katzenstein, M. Bassett, A. Herz, 2006, International journal of STD & AIDS.

Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.

D. Katzenstein, T. Merigan, M. Winters, 1994, Journal of Infectious Diseases.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa

D. Katzenstein, R. Kantor, A. Sohn, 2013, Journal of the International AIDS Society.

Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.

D. Katzenstein, M. Young, R. Dewar, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Immunodeficiency Virus Type 1 Populations in Blood and Semen

B. Walker, D. Katzenstein, G. Learn, 1998, Journal of Virology.

Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation

Tommy F. Liu, D. Katzenstein, R. Shafer, 2010, PloS one.

Novel and Promiscuous CTL Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C HIV Type 1 Infection from Southern Africa1

D. Katzenstein, C. Gray, H. Sheppard, 2004, The Journal of Immunology.

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

S. Hammer, D. Katzenstein, R. D’Aquila, 2003, The Journal of infectious diseases.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.

S. Hammer, D. Katzenstein, A. Collier, 1999, AIDS.

Adherence as a particular issue with protease inhibitors.

D. Katzenstein, 1997, The Journal of the Association of Nurses in AIDS Care : JANAC.

Maternal HIV-1 antibody and vertical transmission in subtype C virus infection.

R. M. Hendry, D. Katzenstein, M. Mbizvo, 2002 .

Bordetella bronchiseptica bacteremia.

D. Katzenstein, M. Jordan, L. Ciofalo, 1984, The Western journal of medicine.

Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients.

D. Katzenstein, T. Merigan, G. Gerna, 1998, AIDS Research and Human Retroviruses.

Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy

D. Katzenstein, R. Kantor, S. Kassaye, 2009, Journal of acquired immune deficiency syndromes.

Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8+ T Cells: Correlation with Viral Load

D. Katzenstein, C. Gray, H. Sheppard, 2004, Journal of Virology.

Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa

D. Katzenstein, D. Israelski, L. Thairu, 2011, AIDS care.

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

D. Katzenstein, T. Merigan, R. Shafer, 1993, The Journal of infectious diseases.

Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors

D. Katzenstein, R. Shafer, D. Pillay, 2014, Antimicrobial Agents and Chemotherapy.

Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.

D. Katzenstein, S. Rusakaniko, L. Zijenah, 2006, The Central African journal of medicine.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS Medicine.

Botulism, type A, and treatment with guanidine

D. Katzenstein, L. Davis, J. Koster, 1979, Annals of neurology.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

T. F. Rinke de Wit, D. Katzenstein, R. Shafer, 2015, PloS one.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

D. Katzenstein, N. Ford, R. Shafer, 2013, The Journal of infectious diseases.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa

D. Katzenstein, Z. El-Khatib, M. Petzold, 2010, AIDS (London).

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

D. Katzenstein, J. Crump, J. Bartlett, 2012, AIDS.

Correlates of HIV Test Results Seeking and Utilization of Partner Counseling Services in a Cohort of Male Factory Workers in Zimbabwe

D. Katzenstein, W. Mcfarland, M. Mbizvo, 2000, AIDS and Behavior.

Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

D. Katzenstein, Z. El-Khatib, M. Petzold, 2011, Journal of AIDS & clinical research.

Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic

D. Katzenstein, K. Nathoo, C. Nhachi, 2017, Journal of AIDS and HIV research.

Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India

D. Katzenstein, R. Kantor, K. Mayer, 2009, Antiviral therapy.

Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

D. Katzenstein, R. Kantor, K. Mayer, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance in non-subtype B HIV-1.

Rami Kantor, David Katzenstein, D. Katzenstein, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.

D. Katzenstein, M. Winters, R. Bosch, 2003, The Journal of infectious diseases.

HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed

Robert Shafer, David Katzenstein, B. Efron, 1999, Annals of Internal Medicine.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

D. Katzenstein, R. Kantor, S. Oka, 2009, Journal of virological methods.

Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.

R. M. Hendry, D. Katzenstein, J. Phair, 1990, AIDS research and human retroviruses.

Antiretroviral therapy for human immunodeficiency virus infection in 1997.

D. Katzenstein, D A Katzenstein, 1997, The Western journal of medicine.

Characterization of the HIV‐1 Specific Humoral Immune Response During Highly Active Antiretroviral Therapy (HAART)

D. Katzenstein, A. Zolopa, D. Israelski, 2001, Journal of acquired immune deficiency syndromes.

Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy

B. Efron, D. Katzenstein, T. Merigan, 1994, Annals of Internal Medicine.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

D. Katzenstein, P. Sax, R. Bosch, 2012, The Journal of infectious diseases.

Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.

D. Katzenstein, T. Merigan, D. Batts, 1994, The Journal of infectious diseases.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment

Rami Kantor, D. Katzenstein, R. Kantor, 2003, Journal of Virology.

Primary subtype C HIV-1 infection in Harare, Zimbabwe.

D. Katzenstein, J. Mullins, M. Mbizvo, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102

D. Katzenstein, M. Winters, P. Tebas, 2006, Journal of acquired immune deficiency syndromes.

Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots

D. Katzenstein, R. Shafer, B. Pinsky, 2016, Journal of Clinical Microbiology.

The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.

D. Katzenstein, J. Mohle-Boetani, M. Holodniy, 1992, The Western journal of medicine.

Global analysis of sequence diversity within HIV-1 subtypes across geographic regions.

D. Katzenstein, J. Hogan, S. Istrail, 2012, Future virology.

International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus.

D. Katzenstein, G. Quinnan,, L. Vujcic, 1990, AIDS research and human retroviruses.

Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans.

D. Katzenstein, T. Quinn, S. Rastogi, 1990, Journal of acquired immune deficiency syndromes.

Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe

D. Katzenstein, W. Mcfarland, M. Bassett, 2002, HIV Clinical Trials.

Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes

D. Katzenstein, J. Blackard, M. Essex, 1997, Journal of virology.

Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays

D. Katzenstein, T. Merigan, R. Shafer, 2005, Journal of acquired immune deficiency syndromes.

Genetic correlates of efavirenz hypersusceptibility

Ronald J Bosch, D. Katzenstein, J. Mellors, 2004, AIDS.

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230

D. Katzenstein, J. Bartlett, N. Kumarasamy, 2016, Open forum infectious diseases.

CCR5- and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic

D. Katzenstein, E. Arts, C. Herrera, 2009, Journal of Virology.

Journal of the International Aids Society the Hiv-1 Non-subtype B Workgroup: an International Collaboration for the Collection and Analysis of Hiv-1 Non-subtype B Data Hiv Diversity and Drug Resistance the Global Paradox

D. Katzenstein, R. Shafer, R. Kantor, 2022 .

The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data.

D. Katzenstein, R. Shafer, R. Kantor, 2005, MedGenMed : Medscape general medicine.

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

S. Hammer, D. Katzenstein, H. Alexander, 2001, The Journal of infectious diseases.

Zimbabwe . Syphilis serology and HIV infection in Harare ,

D. Katzenstein, M. Bassett, P. Mason, 2000 .

Syphilis serology and HIV infection in Harare, Zimbabwe.

D. Katzenstein, M. Bassett, D. Katzenstein, 1999, Sexually transmitted infections.

Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2006, Antimicrobial Agents and Chemotherapy.

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.

D. Katzenstein, R. Shafer, R. Kantor, 2002, AIDS research and human retroviruses.

HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.

D. Katzenstein, W. Mcfarland, M. Mbizvo, 1996, AIDS.

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes

Lynn Morris, Soo-Yon Rhee, Rami Kantor, 2006, AIDS.

Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

D. Katzenstein, L. Zijenah, S. Gholamin, 2012, Journal of AIDS & clinical research.

HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India.

D. Katzenstein, R. Kantor, K. Mayer, 2005, AIDS research and human retroviruses.

Measuring quality of life in early HIV disease: the modular approach

S. Hammer, D. Katzenstein, W. Lenderking, 1997, Quality of Life Research.

Human immunodeficiency virus type 1 RNA shedding in the female genital tract.

D. Katzenstein, W. Mcfarland, C. Goulston, 1998, The Journal of infectious diseases.

Risk factors for prevalent and incident HIV infection in a cohort of volunteer blood donors in Harare, Zimbabwe: implications for blood safety.

D. Katzenstein, W. Mcfarland, D. Mvere, 1997, AIDS.

Sexual behaviour and risk assessment of HIV seroconvertors among urban male factory workers in Zimbabwe.

D. Katzenstein, S. Ray, R. Machekano, 1998, Social science & medicine.

Polymerase chain reaction detection of Haemophilus ducreyi DNA.

D. Katzenstein, P. Mason, L. Gwanzura, 1998, Sexually transmitted infections.

Plasma carnitine in HIV-associated neuropathy.

D. Katzenstein, C. Yiannoutsos, G. Schifitto, 2001, AIDS.

The extent of non‐adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker

S. Hammer, D. Katzenstein, H. Kastrissios, 1998, AIDS.

Combination therapies for HIV infection and genomic drug resistance.

D. Katzenstein, 1997, Lancet.

Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting

D. Katzenstein, V. Robertson, J. Metcalfe, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

D. Katzenstein, W. K. Henry, P. Tebas, 2008, PloS one.

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

D. Katzenstein, J. Bartlett, W. Stevens, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Assessing resistance costs of antiretroviral therapies via measures of future drug options.

Victor DeGruttola, Hongyu Jiang, David Katzenstein, 2003, The Journal of infectious diseases.

Infant Feeding: Knowledge, Attitudes and Practices Among Women in Zimbabwe

D. Katzenstein, M. Bassett, A. Shetty, 2000 .

hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testing

D. Katzenstein, Z. Chirenje, B. Pinsky, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Of molecules, macaques and global AIDS.

D. Katzenstein, 2006, AIDS (London).

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

D. Katzenstein, P. Sax, E. Daar, 2014, Clinical Infectious Diseases.

HIV RNA and genotype in resource-limited settings: can we do better?

D. Katzenstein, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/μl and below 100 cells/μl

S. Hammer, D. Katzenstein, C. Spino, 1999 .

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

Lee Bacheler, Ronald J Bosch, D. Katzenstein, 2003, AIDS.

Whole-Genome Analysis of Cervical Human Papillomavirus Type 35 from rural Zimbabwean Women

D. Katzenstein, B. Pinsky, M. Sahoo, 2020, Scientific Reports.

Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels

D. Katzenstein, C. Yiannoutsos, G. Schifitto, 2002, AIDS.

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.

D. Katzenstein, T. Merigan, R. Shafer, 1995, The Journal of infectious diseases.

Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection.

D. Katzenstein, T. Merigan, M. Winters, 1996, The Journal of infectious diseases.

HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.

D. Katzenstein, T. Merigan, R. Shafer, 1994, Journal of acquired immune deficiency syndromes.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

D. Katzenstein, J. Crump, J. Bartlett, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe

D. Katzenstein, Z. Chirenje, Anat Rosenthal, 2020, BMC Women's Health.

Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa.

D. Katzenstein, 2006, The Journal of infectious diseases.

Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.

D. Katzenstein, T. Merigan, R. Shafer, 1993, Journal of acquired immune deficiency syndromes.

HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe.

D. Katzenstein, R. Shafer, C. Contag, 2000, AIDS Research and Human Retroviruses.

Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting

D. Katzenstein, S. Rusakaniko, M. Borok, 2006, Journal of Translational Medicine.

Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions

Soriano, D. Katzenstein, R. Shafer, 2003 .

Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment

D. Katzenstein, M. Gandhi, J. Metcalfe, 2021, Journal of acquired immune deficiency syndromes.

Estimating HIV incidence from age‐specific prevalence data: comparison with concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe

D. Katzenstein, C. Donnelly, R. Anderson, 1998, AIDS.

HIV seroconversion among factory workers in Harare: who is getting newly infected?

D. Katzenstein, M. Mbizvo, M. Bassett, 1997, The Central African journal of medicine.

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

D. Katzenstein, R. Shafer, C. Petropoulos, 2001, AIDS.

Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why?

D. Katzenstein, 2003, Journal of the International Association of Physicians in AIDS Care.

Mother-to-child transmission of HIV-1 and infant mortality in the first six months of life, in the era of Option B Plus combination antiretroviral therapy.

D. Katzenstein, L. Zijenah, T. Bandason, 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.

S. Hammer, D. Katzenstein, C. Spino, 2000 .

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2004 .

Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment.

D. Katzenstein, T. Merigan, L. Mole, 1992, Journal of acquired immune deficiency syndromes.

Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults

Mark M. Davis, D. Katzenstein, M. Desai, 2014, Journal of Virology.

HIV therapeutics: confronting adherence.

D. Katzenstein, G. Wolfe, A. Williams, 1997, The Journal of the Association of Nurses in AIDS Care : JANAC.

Community-based self-collected human papillomavirus screening in rural Zimbabwe

D. Katzenstein, Z. El-Khatib, Z. Chirenje, 2019, BMC Public Health.

Lethal infection with murine cytomegalovirus after early viral replication in the spleen.

D. Katzenstein, M. Jordan, G. S. Yu, 1983, The Journal of infectious diseases.

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

S. Hammer, D. Katzenstein, R. Schooley, 1998, JAMA.

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

S. Hammer, D. Katzenstein, D. Richman, 1997, Journal of the American Medical Association (JAMA).

Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of the International AIDS Society—USA Panel

S. Hammer, D. Katzenstein, R. Schooley, 1997 .

Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe.

D. Katzenstein, W. Mcfarland, M. Mbizvo, 1998, The Central African journal of medicine.

Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors

D. Katzenstein, R. Shafer, D. Pillay, 2014, Antimicrobial Agents and Chemotherapy.

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe

D. Katzenstein, M. Egger, A. Spoerri, 2018, Open forum infectious diseases.

The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time

D. Katzenstein, D. Stevens, K. Clemons, 2015, Critical reviews in microbiology.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa

D. Katzenstein, Z. El-Khatib, M. Petzold, 2010, AIDS.

Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe

D. Katzenstein, S. Kassaye, G. Woelk, 2009, AIDS Care.

Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202

D. Katzenstein, P. Sax, A. Zolopa, 2013, HIV clinical trials.

Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe

D. Katzenstein, T. Wilsgaard, R. Ferrand, 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.